From mother to baby: antenatal exposure to monoclonal antibody biologics.

We describe the potential risks of infections and reported hematological and immunological effects of antenatal mAbs exposure on the infant and provide guidance on the management of the exposed infant. Expert opinion: Exposed infants should be monitored closely. Certain mAb exposures require specific testing and management. Safety monitoring should be done in a multidisciplinary approach and should include pediatric care providers. The current clinical experience with anti-tumor necrosis factor agents in pregnancy cannot be extrapolated to other mAbs. Long term observational studies and a multicenter international registry are needed to better appreciate the impact of exposure, especially to newer mAbs. PMID: 30570400 [PubMed - as supplied by publisher] (Source: Expert Review of Clinic...

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://bit.ly/2rLJPL8